Nebenwirkungen · Darunavir Krka
Darunavir Krka 600 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 62
HOS-225838 · Präparat HOS-217490
The safety assessment in paediatric patients is based on the 48-week analysis of safety data from three Phase II studies. The following patient populations were evaluated (see section 5.1): 80 ART-experienced HIV-1 infected paediatric patients aged from 6 to 17 years and weighing at least 20 kg who received darunavir tablets with low dose ritonavir twice daily in combination with other antiretroviral agents. 21 ART-experienced HIV-1 infected paediatric patients aged from 3 to < 6 years and weighing 10 kg to < 20 kg (16 participants from 15 kg to < 20 kg) who received darunavir oral suspension with low dose ritonavir twice daily in combination with other antiretroviral agents. 12 ART-naïve HIV-1 infected paediatric patients aged from 12 to 17 years and weighing at least 40 kg who received darunavir tablets with low dose ritonavir once daily in combination with other antiretroviral agents (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-28T02:00:00Z · SHA-256 42a250050090ba77cfec6bb0ff0fc9dbbb4e1a422df7d45e8efc6fc459616a05 · Passage 1a061bf85a3b2a6d5845d6bbbe2148de4a6deb9dfa27e6a7bb18b5e06e2697a8 · Zeichen 11788–12760 im Abschnitt